Skip to content
OpenCapital
Get started

Corvus Pharmaceuticals CRVS Q3 2025 earnings

Reported November 4, 2025 · After market close

EPS-$0.12Beat by $0.02
EPS estimate-$0.14

Next report

Aug 6, 2026 (In 1 week)
EPS estimate-$0.17

Financials

Q3 2025

Income statement

See full
Operating income-$10.6M-45.7%
Net income-$10.2M+74.7%
EPS (diluted)-$0.12+80.0%

Balance sheet

See full
Cash & equivalents$2.9M-38.7%
Total debt$1.0M+186%
Total equity$71.8M+478%
Total assets$80.5M+36.8%

Cash flow

See full
Operating cash flow-$9.6M-51.3%
CapEx-—
Free cash flow-$9.6M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$549.17M+66.3%
Enterprise value$547.31M+67.9%

Returns & leverage

See full
Return on equity-35.8%-16.2pp
Debt / equity0×0.0×
Current ratio8.3×+7.4×

Versus estimates

Diluted EPS

Q1 2026-$0.15Miss by $0.01Q4 2025-$0.15Miss by $0.01
Q3 2025-$0.12Beat by $0.02
Q2 2025-$0.10Beat by $0.03Q1 2025-$0.13In lineQ4 2024-$0.18Miss by $0.06

Ask the moment Corvus Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Corvus Pharmaceuticals report Q3 2025 earnings?
Corvus Pharmaceuticals (CRVS) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Corvus Pharmaceuticals's Q3 2025 revenue and EPS?
Corvus Pharmaceuticals reported eps of $-0.12 for Q3 2025.
Did Corvus Pharmaceuticals beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.14 by $0.02.
How did Corvus Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 9.1% from $-0.11.
Where can I find Corvus Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001171843-25-006973) and the 10-Q periodic report (0001104659-25-106259) directly on SEC EDGAR. The filing index links above go to sec.gov.